Takahisa Mikami, MD, Tufts Medical Center, Boston, MA, comments on the next steps in studying neurological adverse events caused by immune checkpoint inhibitors. Dr Mikami highlights the importance of early recognition of neurological complications and how the analysis of pharmacovigilance data can be helpful. However, he highlights the problems of a self-report database and the lack of detailed clinical data. Dr Mikami believes that more studies on the toxicity mechanisms associated with immune checkpoint inhibitors are needed. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.